Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia

American Journal of Clinical Pathology

Volumn 138, Issue 5, 2012, Pages 744-750

  Zhou, Yi ^a   Jorgensen, Jeffrey L ^a   Wang, Sa A ^a   Ravandi, Farhad ^a   Cortes, Jorge ^a   Kantarjian, Hagop M ^a   Medeiros, L Jeffrey ^a   Konoplev, Sergej ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

2 integrin; Acute progranulocytic leukemia; CD11a; CD18; Flow cytometry

Indexed keywords

ANTIBODY; ARSENIC TRIOXIDE; CD18 ANTIGEN; CD2 ANTIGEN; CD34 ANTIGEN; HLA DR ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RETINOIC ACID; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTIGENS, CD11A; ANTIGENS, CD18; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84868119408     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPQU9R3FSLKFMI     Document Type: Article

References (17)

1. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106:3342-3347.
2. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol.2009;27:504-510.
3. Neame PB, Soamboonsrup P, Leber B, et al. Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants. Am J Hematol. 1997;56:131-142. (Pubitemid 27486423)
4. Castoldi GL, Liso V, Specchia G, et al. Acute promyelocytic leukemia: morphological aspects. Leukemia. 1994;8(suppl 2):S27-S32.
5. Grimwade D, Biondi A, Mozziconacci MJ, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies." Blood. 2000;96:1297-1308.
6. Paietta E, Goloubeva O, Neuberg D, et al. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry B Clin Cytom. 2004;59:1-9. (Pubitemid 38581544)
7. Di Noto R, Schiavone EM, Ferrara F, et al. Expression and ATRA-driven modulation of adhesion molecules in acute promyelocytic leukemia. Leukemia. 1994;8:1900-1905. (Pubitemid 24363066)
8. Wu JJ, Cantor A, Moscinski LC. beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid. Leuk Res. 2007;31:49-57. (Pubitemid 44709747)
9. Dong HY, Kung JX, Bhardwaj V, et al. Flow cytometry rapidly identifies all acute promyelocytic leukemias with high specificity independent of underlying cytogenetic abnormalities. Am J Clin Pathol. 2011;135:76-84.
10. Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol.2003;16:369-385.
11. Lin P, Hao S, Medeiros LJ, et al. Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis. Am J Clin Pathol. 2004;121:402-407. (Pubitemid 38298174)
12. Di Noto R, Lo Pardo C, Schiavone EM, et al. All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Leuk Lymphoma.1996;21:201-209. (Pubitemid 26138937)
13. Ruchaud S, Duprez E, Gendron MC, et al. Two distinctly regulated events, priming and triggering, during retinoidinduced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc Natl Acad Sci U S A. 1994;91:8428-8432.
14. Claxton DF, Reading CL, Nagarajan L, et al. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood. 1992;80:582-586.
15. Albano F, Mestice A, Pannunzio A, et al. The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. Haematologica.2006;91:311-316.
16. Adriaansen HJ, te Boekhorst PA, Hagemeijer AM, et al. Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. Blood.1993;81:3043-3051. (Pubitemid 23162124)
17. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol. 2001;32:545-552. (Pubitemid 32506526)